ERBB2 and breast cancer: Trastuzumab (Herceptin; Roche, Basel, Switzerland), a HER2-directed humanized monoclonal antibody, has been shown to improve both disease-free and overall survival in HER2-positive (HER2+) breast cancer patients [13].